FADOLMIDINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H14N2O
Molecular Weight	214.2631
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=C2CCC(CC3=CNC=N3)C2=C1

InChI

InChIKey=VTZPAJGVRWKMAG-UHFFFAOYSA-N

InChI=1S/C13H14N2O/c16-12-4-3-9-1-2-10(13(9)6-12)5-11-7-14-8-15-11/h3-4,6-8,10,16H,1-2,5H2,(H,14,15)

HIDE SMILES / InChI

Molecular Formula	C13H14N2O
Molecular Weight	214.2631
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.recropharma.com/product-pipeline/fadolmidine | https://www.ncbi.nlm.nih.gov/pubmed/15179442 | https://www.ncbi.nlm.nih.gov/pubmed/18930723

Fadolmidine (MPV 2426) is an alpha2-adrenoceptor agonist. Fadolmidine displayed high affinity and full agonist efficacy at all three human alpha2-adrenoceptor subtypes (A, B and C). Various preclinical models of pain have been employed and have demonstrated fadolmidine potential as an analgesic, including its potential for use in neuropathies and post-operative pain. A Phase II clinical trial successfully demonstrated that intrathecal fadolmidine, in combination with bupivacaine, produced analgesic effects compared to bupivacaine alone in bunionectomy patients.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Alpha-2A adrenergic receptor 26 Target ID: P08913 Gene ID: 150.0 Gene Symbol: ADRA2A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18930723	Agonist 2752	0.4 nM [EC50]
Alpha-2B adrenergic receptor 13 Target ID: P18089 Gene ID: 151.0 Gene Symbol: ADRA2B Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18930723	Agonist 2752	4.9 nM [EC50]
Alpha-2C adrenergic receptor 11 Target ID: P18825 Gene ID: 152.0 Gene Symbol: ADRA2C Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/18930723	Agonist 2752	0.5 nM [EC50]

PubMed

Title	Date	PubMed
Pharmacological profile of intrathecal fadolmidine, a alpha2-adrenoceptor agonist, in rodent models.	2009-12	19826791
In vitro and in vivo profiling of fadolmidine, a novel potent alpha(2)-adrenoceptor agonist with local mode of action.	2008-12-03	18930723
Peripheral suppression of arthritic pain by intraarticular fadolmidine, an alpha 2-adrenoceptor agonist, in the rat.	2007-07	17578982
Fadolmidine-induced ocular hypotension in normotensive rabbits.	2005-02	15720782
Alpha(2A) adrenoceptors contribute to feedback inhibition of capsaicin-induced hyperalgesia.	2004-07	15220790
Antinociceptive properties of fadolmidine (MPV-2426), a novel alpha2-adrenoceptor agonist.	2004	15179442

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:27:55 GMT 2025` Edited by `admin` on `Mon Mar 31 18:27:55 GMT 2025`
Record UNII	WLN5FGH1CY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Fadolmidine [WHO-DD]

Preferred Name

English

FADOLMIDINE

Official Name

English

fadolmidine [INN]

Common Name

English

3-(IMIDAZOL-4-YLMETHYL)-5-INDANOL

Systematic Name

English

RADOLMIDINE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29713